Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29866656 | 0.81 | PREP (0.39) | PTPN2PTPN1PTPN6CHRM2CHRM1 | |
| SCHEMBL25165581 | 0.81 | PREP (0.39) | PTPN2PTPN1PTPN6CHRM2CHRM1 | |
| SCHEMBL1639677 | 0.81 | PREP (0.39) | PTPN2PTPN1PTPN6CHRM2CHRM1 | |
| SCHEMBL527701 | 0.75 | TSHR (0.56) | CHRM2CHRM1CHRM3SETD7GPR119 | |
| SCHEMBL344752 | 0.75 | TSHR (0.56) | CHRM2CHRM1CHRM3SETD7GPR119 | |
| SCHEMBL271429 | 0.75 | TSHR (0.56) | CHRM2CHRM1CHRM3SETD7GPR119 | |
| SCHEMBL6253270 | 0.74 | LMNA (0.36) | GPR119PREPHSD17B10NR1H2 | |
| SCHEMBL28923159 | 0.74 | USP2 (0.46) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL24069887 | 0.74 | USP2 (0.46) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL30477339 | 0.73 | PREP (0.41) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140919-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2024-05-02 | — | — | US | claimed |
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2023-08-10 | — | — | US | claimed |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2021-05-20 | — | — | US | claimed |
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2021-05-06 | — | — | US | claimed |
| EP-3768660-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | Denali Therapeutics Inc. (US) | 2021-01-27 | — | — | EP | claimed |
| EP-3665156-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2020-06-17 | — | — | EP | claimed |
| CN-111094233-A | Compounds, compositions and methods | 戴纳立制药公司 | 2020-05-01 | — | — | CN | claimed |
| WO-2019183589-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. (US) | 2019-09-26 | — | — | WO | claimed |
| WO-2019032743-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2019-02-14 | — | — | WO | claimed |
| CN-118239937-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118239938-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240140919-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2024-05-02 | — | — | US | disclosed |
| US-11851440-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2021-05-06 | — | — | US | disclosed |
| EP-3768660-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | Denali Therapeutics Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-3665156-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| CN-111094233-A | Compounds, compositions and methods | 戴纳立制药公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2019183589-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019032743-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | PTPN2 3744/4885PTPN1 4429/4885PTPN6 4150/4885 |
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | PTPN2 3744/4885PTPN1 4429/4885PTPN6 4150/4885 |
| US-11851440-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | EIF4EBP1, EIF4B, EIF2B2 | PTPN2 4118/4885PTPN1 4421/4885PTPN6 4222/4885 |
| US-20240140919-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | PTPN2 3744/4885PTPN1 4429/4885PTPN6 4150/4885 |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | EIF4EBP1, EIF4B, EIF4E | PTPN2 3689/4885PTPN1 4218/4885PTPN6 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.